Use of Ovarian Tumor Markers in Prediction of Malignancy Risk in Pediatric and Adolescent Patients
Timestops (2)
Tools Used
Topic Overview
Key Takeaways
- Beta-HCG was the most valuable tumor marker, appearing in every top-performing combination for predicting ovarian malignancy in pediatric patients.
- Some tumor marker panels achieved 100% negative predictive value, meaning no cancers were misclassified as benign in this 300+ patient cohort.
- Preoperative tumor marker panels can guide ovarian-sparing surgery decisions and reduce unnecessary operations in children with ovarian masses.
- AFP and beta-HCG combinations significantly improve malignancy risk stratification compared to clinical assessment alone in pediatric ovarian tumors.
- Accurate preoperative risk assessment using tumor markers helps preserve fertility by identifying truly benign masses that don't require aggressive surgery.
Keywords
Hashtags
Transcript
When a child presents with an ovarian mass, how confident are we that it's benign before we operate? I'm Lizzie Lee from Cincinnati Children's, and this is an article you should know about. Surgeons often rely on tumor markers like AFP and beta HCG to estimate malignancy risk, but how well do they actually work? In this large study of more than 300 pediatric and adolescent patients, researchers analyzed how individual markers and combinations predicted cancer. The standout beta HC. appeared in every top performing combination. Some marker panels achieved extremely high accuracy, and some combinations had a 100% negative predictive value, meaning no cancer was misclassified as benign. So the message is clear, tumor markers can improve preoperative risk stratification, helping preserve ovaries when appropriate and avoiding unnecessary surgery. Let us know what you think in the comments below and stay tuned for more articles that you should know about.